Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | RHEB | Q15382 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 5/20 | 0.33 |
| ▸ | BRAF | P15056 | 4/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7882132 | 0.92 | KDR (0.32) | RHEBRAF1BRAFKDR | |
| SCHEMBL7877803 | 0.88 | KDR (0.38) | RHEBRAF1BRAFKDRHTR2A | |
| SCHEMBL7884357 | 0.87 | KMT2A (0.37) | P2RX3RAF1BRAFKDRLNPEP | |
| SCHEMBL7881922 | 0.87 | KDR (0.38) | RAF1BRAFKDRSLC6A4LNPEP | |
| SCHEMBL7877940 | 0.86 | MAPK14 (0.39) | RHEBRAF1BRAFKDRHTR2A | |
| SCHEMBL7877855 | 0.85 | LOXL2 (0.33) | RHEBHTR2ASLC6A4 | |
| SCHEMBL7877544 | 0.85 | SLC6A4 (0.38) | RHEBHTR2ASLC6A4 | |
| SCHEMBL7881485 | 0.84 | PPARG (0.39) | RHEBHTR2ASLC6A4 | |
| Hydrochloric Acid SCHEMBL7881328 | 0.84 | SLC6A4 (0.37) | RHEBHTR2ASLC6A4 | |
| SCHEMBL7877840 | 0.84 | SLC6A4 (0.36) | P2RX3BRAFKDRHTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |